Tacrolimus Clinical Trials
47 recruitingDrug
Phase 232Phase 19Phase 37Phase 44Not Applicable1Early Phase 11
Showing 1–20 of 47 trials
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
MDSImmunodeficiencyGATA2
National Cancer Institute (NCI)144 enrolled1 locationNCT01861106
Recruiting
Phase 2
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Sickle Cell Disease
Memorial Sloan Kettering Cancer Center24 enrolled6 locationsNCT05736419
Recruiting
Phase 1
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting
Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
Biogen180 enrolled85 locationsNCT06962800
Recruiting
Phase 2
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2Phase 3
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled73 locationsNCT07204275
Recruiting
Phase 2Phase 3
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Kidney Transplant Rejection
Sanofi526 enrolled2 locationsNCT07412470
Recruiting
Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
Allogeneic Stem Cell Transplant Recipient
Hackensack Meridian Health209 enrolled3 locationsNCT07214688
Recruiting
Phase 2Phase 3
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
End Stage Renal Disease
Roberto Gedaly78 enrolled1 locationNCT03321656
Recruiting
Phase 2
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Janssen Research & Development, LLC300 enrolled93 locationsNCT06120140
Recruiting
Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Refractory and/or Relapsed Metastatic Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60 enrolled3 locationsNCT01804634
Recruiting
Phase 2
Allo HSCT for High Risk Hemoglobinopathies
Sickle Cell DiseaseHemoglobinopathiesGraft Failure
Masonic Cancer Center, University of Minnesota62 enrolled1 locationNCT06872333
Recruiting
Phase 2
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+2 more
Fred Hutchinson Cancer Center120 enrolled3 locationsNCT03970096
Recruiting
Phase 2
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
MyelofibrosisSplenomegaly
M.D. Anderson Cancer Center30 enrolled1 locationNCT06345495
Recruiting
Phase 1
Trial of Cell Based Therapy for DMD
Duchenne Muscular Dystrophy
Masonic Cancer Center, University of Minnesota8 enrolled1 locationNCT06692426
Recruiting
Phase 1
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Recurrent Adult Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic Leukemia+1 more
University of Chicago30 enrolled1 locationNCT02333162
Recruiting
Phase 4
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.
Solid Organ Transplant
Murdoch Childrens Research Institute45 enrolled1 locationNCT06529536
Recruiting
Phase 2
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Myelodysplastic/Myeloproliferative NeoplasmPrimary MyelofibrosisSecondary Myelofibrosis
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07228624
Recruiting
Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic Malignancies
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07359859
Recruiting
Phase 3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Renal Allograft Recipients
Bristol-Myers Squibb102 enrolled38 locationsNCT04877288